ClinicalTrials.gg

Program

zopapogene imadenovec

Also written as “Zopapogene imadenovec-drba”, “Zopapogene imadenovec (Zopa)” and “PRGN-2012 - Phase I; Dose Level 1”.

Its studies are mostly in Recurrent respiratory papillomatosis, led by Precigen.

Furthest: phase 4, since Aug 1, 20243 company-led studies, 3 open or runningNext primary completion: Dec 2, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Precigen33 open or runningphase 4since Aug 1, 2024Jan 23, 2021Dec 2, 2027phase 4 · NCT06538480

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 23, 2021First study: phase 2 study in Recurrent respiratory papillomatosisFirst studyNCT04724980 · 38 enrolled · United States
  2. Aug 1, 2024Phase 4 study in Recurrent respiratory papillomatosisNCT06538480 · 30 planned · United States
  3. Oct 21, 2026Phase 3 study in Recurrent respiratory papillomatosisNCT07901738 · 15 planned · United States

Ahead

  1. Dec 2, 2027Primary completion: phase 4 study in Recurrent respiratory papillomatosisNCT06538480
  2. Jan 2029Primary completion: phase 3 study in Recurrent respiratory papillomatosisNCT07901738

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07901738Recurrent respiratory papillomatosis · United States3Not yet recruitingJan 202915
NCT06538480Recurrent respiratory papillomatosis · United States4RecruitingDec 2, 202730
NCT04724980Recurrent respiratory papillomatosis · United States2Active, not recruitingJun 5, 202438

How it is read

Names in the registry

  • “Zopapogene imadenovec-drba”, 1 entry
  • “Zopapogene imadenovec (Zopa)”, 1 entry
  • “PRGN-2012 - Phase I; Dose Level 1”, 1 entry
  • “PRGN-2012 - Phase I; Dose Level 2”, 1 entry
  • “PRGN-2012 - Phase II; Dose Level 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.